Lower blood pressure in floxed angiotensinogen mice after adenoviral delivery of Cre-recombinase.
Recent experimental evidence suggests a role for tissue renin-angiotensin systems in the development of hypertension. To test the importance of tissue renin-angiotensin systems in the development and maintenance of angiotensin II-dependent hypertension, we generated a transgenic model in which exon 2 of the human angiotensinogen gene is flanked by loxP sites (hAGT(flox)) so that this region of the gene can be deleted by the cre-recombinase. Double transgenic human renin and hAGT(flox) (R(+)/A(+flox)) mice of two independent lines exhibited elevated blood pressure. Acute administration of an adenovirus containing cre-recombinase (Adcre) lowered blood pressure by 30 mm Hg over a 4-day period as measured with fluid filled catheters. The chronic effect of Adcre administration on blood pressure was determined by radiotelemetry in a separate group of R(+)/A(+flox) mice. Blood pressure decreased by 25 mm Hg from baseline by day 8 post-Adcre, but increased on each day thereafter until it was 90% of baseline by day 21 post-Adcre. Expression analysis indicated the absence of detectable hAGT mRNA in the liver at day 5 post-Adcre, but reappeared at normal levels at days 14 to 21 post-Adcre. These studies suggest that Adcre is effective for acute, but not chronic, elimination of hepatic hAGT. Chronic elimination of hepatic hAGT will likely require the use of transgenic mice endogenously expressing cre-recombinase in the liver.
Stec
David E
DE
Department of Internal Medicine, The University of Iowa College of Medicine, Iowa City, Iowa 52242, USA.
Keen
Henry L
HL
Sigmund
Curt D
CD
D000256:Adenoviridae / Q000235:genetics; D000808:Angiotensinogen / Q000009:adverse effects; D000818:Animals; D001794:Blood Pressure; D004195:Disease Models, Animal; D015316:Genetic Therapy; D005822:Genetic Vectors; D006973:Hypertension / Q000235:genetics / Q000628:therapy*; D019426:Integrases / Q000235:genetics / Q000627:therapeutic use*; D051379:Mice; D008822:Mice, Transgenic; D014764:Viral Proteins / Q000235:genetics / Q000627:therapeutic use*
D014764:Viral Proteins; D000808:Angiotensinogen; C045073:Cre recombinase; D019426:Integrases